Celgene Thalomid Promotions For Off-Label Cancer Use Draw FDA Warning
Executive Summary
Thalomid sales representatives have disseminated third-party press releases that promote off-label use of the thalidomide capsules for multiple myeloma, an FDA warning letter to Celgene states.
You may also be interested in...
Rx Promotion Remains Potential Political Liability, Attorneys Warn
Pharmaceutical companies should prepare for increased Congressional scrutiny of promotional activities heading into the 2002 mid-term elections, attorney John Kamp (Wiley, Rein and Faulding, Washington, D.C.) told a Drug Information Association marketing workshop.
Rx Promotion Remains Potential Political Liability, Attorneys Warn
Pharmaceutical companies should prepare for increased Congressional scrutiny of promotional activities heading into the 2002 mid-term elections, attorney John Kamp (Wiley, Rein and Faulding, Washington, D.C.) told a Drug Information Association marketing workshop.
Celgene Seeks Additional Oncologic To Leverage Thalomid Sales Force
Celgene is planning to in-license an oncology product to be detailed alongside Thalomid (thalidomide), CEO John Jackson told the Biotechnology Industry Organization's CEO & Investor Conference in New York City Feb. 21.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: